Table 1.
Basic characteristics of included studies.
| Study | Country | Study design | Cases | Disease category (cases, n) | ANCA | Follow-up months | Remission | Study quality score |
|---|---|---|---|---|---|---|---|---|
| Joy et al. (14) | USA | Case series | 12 | WG (7), MPA (2), NCGN (2), CSS(1) | MPO (3) PR3 (9) | 12 | 6/12 | 5 |
| Koukoulaki and Jayne (29) | UK | Case series | 22 | AASV | N/A | 21.9 ± 14.8* | 18/22 | 5 |
| Stassen et al. (15) | Netherlands | Cohort | 32 | WG (29), MPA (3) | MPO (3) PR3 (29) | 12 (2–58) # | CR: 25/32 PR: 6/32 | 6 |
| Hu et al. (17) | China | Randomized | 35 | MPA (34), WG (1) | MPO (28) PR3 (2) | 6 | 14/18 (IVC: 8/13) | 5 |
| Silva et al. (31) | USA | Cohort | 17 | MPA | MPO (17) | 18 | 13/17 | 6 |
| Han et al. (18) | China | Randomized | 42 | NA | MPO (42) | 6 | 14/18 (IVC: 8/13) | 9 |
| Jones et al. (10) | UK | Randomized | 140 | MPA (49), GPA (91) | MPO (53) PR3 (82) | 18 | 47/70 (IVC: 43/70) | 9 |
| Tuin et al. (19) | Canada | Randomized | 84 | NA | MPO (9) PR3 (75) | 48 | 27/41 (IVC: 35/43) | 9 |
ANCA, Antineutrophil cytoplasmic antibody; AASV, Antineutrophil cytoplasm antibodies associated systemic vasculitis; IVC, Intravenous cyclophosphamide; WG, Wegener's granulomatosis; MPA, Microscopic polyangiitis; GPA, Granulomatosis with polyangiitis; CSS, Churg–Strauss syndrome; NCGN, Necrotizing and crescentic glomerulonephritis alone; MPO, Myeloperoxidase; PR3, Proteinase 3; CR, Complete remission; PR, Partial remission; NA, Not available;
#
Median (range);
*
Mean ± standard variance.